Last updated: February 27, 2026
What Is NDC 54766-0894?
The National Drug Code (NDC) 54766-0894 is associated with a specific pharmaceutical product. According to FDA records, this NDC corresponds to Bupropion Hydrochloride Extended-Release (SR), 150 mg. The drug is used primarily for depression and smoking cessation.
Market Landscape
Industry Overview
The Bupropion market addresses multiple indications:
- Major depressive disorder
- Seasonal affective disorder
- Smoking cessation
The drug's generic versions have increased competition, affecting pricing and market share. The demand remains steady due to its dual indications, with an estimated global market size of approximately USD 1.2 billion in 2022.
Competition & Key Players
Major competitors include:
- GlaxoSmithKline (original manufacturer)
- Mylan (now part of Viatris)
- Teva Pharmaceuticals
- Apple Therapeutics
Generic formulations drive price competition, especially in the US market.
Prescription Volume
In 2021, approximately 15 million prescriptions filled in the US alone, with an annual growth rate of 3%. Generic penetration exceeds 85%, reducing branded drug sales.
Patent & Regulatory Status
Bupropion SR patents have expired, facilitating generic entry. FDA approval for generic equivalents was granted in 2012. Post-expiration patent protections influence market dynamics by enabling multiple competitors.
Price Trends and Projections
Current Pricing
| Parameter |
Details |
| Average wholesale price (AWP) |
USD 0.35 per tablet |
| Average retail price |
USD 0.45 per tablet |
| Estimated per-prescription cost |
USD 25 - USD 35 |
Historical Price Trends
- 2018: Retail price averaged USD 0.60 per tablet
- 2020: Price decreased to USD 0.45 per tablet (due to generic competition)
- 2022: Further decline to USD 0.35 per tablet
Market Drivers
- Increased generic market share pushes prices downward.
- Insurance coverage and pharmacy benefit managers (PBMs) influence net prices.
- Drug rebates and discounts impact actual transaction prices.
Price Projections (2023-2027)
| Year |
Estimated Wholesale Price (USD/Tablet) |
Key Factors |
| 2023 |
USD 0.33 |
Ongoing generic competition |
| 2024 |
USD 0.31 |
Market saturation, further discounting |
| 2025 |
USD 0.30 |
Possible market stabilization |
| 2026 |
USD 0.29 |
Shift toward value-based pricing, inflation adjustment |
| 2027 |
USD 0.28 |
Slight cost decline, increased generic options |
Revenue Implications
Assuming approximately 15 million prescriptions annually, revenue estimates for the drug are:
| Year |
Estimated Gross Revenue (USD billions) |
Assumptions |
| 2023 |
USD 4.95 |
USD 0.33 × 15 million prescriptions |
| 2024 |
USD 4.65 |
USD 0.31 × 15 million prescriptions |
| 2025 |
USD 4.50 |
USD 0.30 × 15 million prescriptions |
| 2026 |
USD 4.35 |
USD 0.29 × 15 million prescriptions |
| 2027 |
USD 4.20 |
USD 0.28 × 15 million prescriptions |
Regulatory and Reimbursement Impact
- The drug's status as a generic limits pricing power.
- Insurance reimbursement policies favor lower-cost generics.
- Any significant regulatory changes, such as new formulation approvals, could influence prices but are unlikely within current market dynamics.
Key Takeaways
- The NDC 54766-0894 corresponds to generic bupropion SR 150 mg.
- The market is highly competitive, leading to a steady decline in wholesale prices over recent years.
- Price projections suggest a gradual decline, with retail prices stabilizing around USD 0.28–0.33 per tablet through 2027.
- Prescribing volume remains stable given the drug's indications and accepted safety profile.
- Revenue from this drug depends on prescription volume and payer discounts; steady prescription numbers imply consistent revenue streams despite declining unit prices.
FAQs
1. How does generic competition influence the pricing of NDC 54766-0894?
The entry of multiple generic manufacturers has caused a significant reduction in wholesale and retail prices, with market saturation limiting potential price increases.
2. What factors could reverse the downward price trend?
Approval of new formulations, shortages, or regulatory restrictions could temporarily stabilize or raise prices. Changes in insurance reimbursement policies could also impact net pricing.
3. Is there potential for price increases due to market exclusivity?
No; patent expiration and rapid generic entry prevent price increases in the current market.
4. How do reimbursement policies affect the market share of this drug?
Payers favor lower-cost generics, leading to increased utilization and market penetration, pressuring prices downward.
5. What are the key considerations for investors or manufacturers?
Investors should monitor prescription trends, patent protections, and regulatory developments. Manufacturers should consider expanding generic portfolio options or alternative formulations to maintain pricing power.
References
[1] U.S. Food & Drug Administration. (2022). Drug Listing. Retrieved from https://dailymed.nlm.nih.gov/dailymed/
[2] IQVIA Institute. (2022). The Use of Medicines in the United States. Market size and prescription data.
[3] FDA. (2012). Abbreviated New Drug Application (ANDA) approvals. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-resources
[4] SSR Health. (2022). Prescription price and volume data.
